EMA Explains Process For Assessing Suitability Of Biomarkers With Concerned Medicines
Executive Summary
A new EU guideline outlines the steps that notified bodies can take to facilitate the European Medicines Agency’s assessment of the appropriateness of a companion diagnostic’s use with a drug.
You may also be interested in...
EU Explains Steps Sponsors Must Take When Using Companion Diagnostics In Drug Development
A new Q&A document from the European Medicines Agency outlines the key steps that pharma companies should take when using companion diagnostics in clinical trials, and the information it expects to see in marketing authorization applications.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.